Fatigue, cancer related
Conditions
Interventions
Group 1: Patients with histologically or cytologically diagnosed various tumor entities for which a therapy with Paclitaxel LIV Pharma is indicated according to the SPC.
Sponsors
LIV Pharma GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Minimum Age 18 years - Informed Consent - Underlying Tumor disease of breast, lung or ovarian - No pregnancy - Therapy with Paclitaxel LIV Pharma - The current therapy was started no more than 12 weeks ago - No simultaneous, further study participation
Exclusion criteria
Exclusion criteria: - Contraindications to the use of oxaliplatin LIV Pharma according to the SmPC. - The current therapy was started more than 12 weeks ago. - The patient is participating in a study at the same time. - Pregnancy is present or the patient is breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Course of Fatiguesyndroms, assessed by MFI questionnaire (mulitdimensional fatigue inventory) at baseline, cycles 2, 4, 6, 8, 10, 12, end of treatment and follow-up visits 1-3 as well as BSA-Questionnaire on physical activity and sports activity assessed at cycles 1, 5 , 9, end of treatment and follow-up examinations 1-3 | — |
Secondary
| Measure | Time frame |
|---|---|
| Course the Quality of Life collected by questionnaire EORTC C30-v 3.0 at baseline, cycles 4, 8, 12, end of treatment and follow-up visits 1 -3 | — |
Countries
Germany
Contacts
Public ContactBurkard Heckelbacher
Datafaber GbR
Outcome results
None listed